

Robert D Mcbane II

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1786110/publications.pdf>

Version: 2024-02-01

200
papers

7,287
citations

61984

43
h-index

66911

78
g-index

202
all docs

202
docs citations

202
times ranked

7811
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2022, 97, 308-324.	3.0	16
2	Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 454-466.	2.1	10
3	Resolution of acute pulmonary embolism using anticoagulation therapy alone in coronavirus disease 2019. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 578-584.e2.	1.6	8
4	Inpatient Management of Pulmonary Embolism: Clinical Characteristics and Mortality in a High-Volume Tertiary Care Center. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	2.1	2
5	Single versus multiple and incidental versus symptomatic subsegmental pulmonary embolism: clinical characteristics and outcome. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 82-90.	2.1	5
6	Risk of venous thromboembolism after COVID-19 vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1638-1644.	3.8	24
7	Artificial intelligence for the evaluation of peripheral artery disease using arterial Doppler waveforms to predict abnormal ankle-brachial index. <i>Vascular Medicine</i> , 2022, 27, 333-342.	1.5	8
8	Spontaneous visceral artery dissections in otherwise normal arteries: Clinical features, management, and outcomes compared with fibromuscular dysplasia. <i>Journal of Vascular Surgery</i> , 2021, 73, 516-523.e2.	1.1	3
9	Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. <i>Oncologist</i> , 2021, 26, e8-e16.	3.7	31
10	Pulmonary venous thrombosis in a patient with COVID-19 infection. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 985-988.	2.1	5
11	Usability of a Digital Registry to Promote Secondary Prevention for Peripheral Artery Disease Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 94-102.	2.4	2
12	Calf vein thrombosis outcomes comparing patients with and without cancer. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1059-1066.	2.1	3
13	Arterial Thrombosis and Coronavirus Disease 2019. <i>Mayo Clinic Proceedings</i> , 2021, 96, 274-276.	3.0	11
14	Arterial Thrombosis and Cancer. <i>Mayo Clinic Proceedings</i> , 2021, 96, 526-528.	3.0	0
15	Reduced calf muscle pump function is a risk factor for venous thromboembolism: a population-based cohort study. <i>Blood</i> , 2021, 137, 3284-3290.	1.4	9
16	Deep vein thrombosis and pulmonary embolism among hospitalized coronavirus disease 2019-“positive” patients predicted for higher mortality and prolonged intensive care unit and hospital stays in a multisite healthcare system. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 1361-1370.e1.	1.6	17
17	Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 388-402.	2.4	51
18	Primary pulmonary artery sarcoma versus pulmonary thromboembolism: a multimodal imaging comparison. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1129-1132.	2.1	2

#	ARTICLE	IF	CITATIONS
19	Calf Vein Thrombosis Outcomes Comparing Anticoagulation and Serial Ultrasound Imaging Management Strategies. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1184-1192.	3.0	7
20	Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis on Frequency of Venous Thromboembolism. <i>American Journal of Cardiology</i> , 2021, 149, 112-118.	1.6	5
21	Demographics and Clinical Outcomes in Patients Older Than 75 Years Treated for Acute Venous Thromboembolism. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, e151-e153.	0.9	0
22	Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19â€“Positive Compared With COVID-19â€“Negative Patients. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1718-1726.	3.0	11
23	Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1861-1873.	3.0	16
24	Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2206-2215.	3.8	11
25	Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2793-2805.	3.0	20
26	Heparin Skin Necrosis in Heparin-Induced Thrombocytopenia. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2492.	3.0	1
27	Major adverse events associated with inducible cardiac ischemia during treadmill exercise testing for peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2021, 74, 1335-1342.e2.	1.1	2
28	Evaluation of Changing Vena Cava Filter Use and Inpatient Hospital Mortality from 2016-2019: A Single-Institution Quality Improvement Project. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 851-858.	2.4	1
29	A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy. <i>Shock</i> , 2021, 55, 700-716.	2.1	31
30	Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. <i>Thrombosis Research</i> , 2021, 207, 150-157.	1.7	24
31	Sequential Pneumatic Compression in the Arm in Neurocritical Patients with a Peripherally Inserted Central Venous Catheter: A Randomized Trial. <i>Neurocritical Care</i> , 2020, 32, 187-192.	2.4	6
32	Apixaban and dalteparin in active malignancyâ€“associated venous thromboembolism: The ADAM VTE trial. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 411-421.	3.8	381
33	Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. <i>European Journal of Haematology</i> , 2020, 104, 88-96.	2.2	24
34	Calf muscle pump function as a predictor of all-cause mortality. <i>Vascular Medicine</i> , 2020, 25, 519-526.	1.5	9
35	In-home Compared With In-Clinic Warfarin Therapy Monitoring in Mechanical Heart Valves: A Population-Based Study. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 511-520.	2.4	9
36	Thromboembolism and the Pandemic. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2073-2075.	2.8	2

#	ARTICLE	IF	CITATIONS
37	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	4.6	21
38	Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2467-2486.	3.0	91
39	End-Stage Renal Disease, Nonvalvular Atrial Fibrillation, and the Warfarin Dilemma. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1099-1101.	3.0	2
40	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Blood</i> , 2020, 136, 1433-1441.	1.4	106
41	Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight. <i>European Journal of Haematology</i> , 2020, 105, 484-494.	2.2	19
42	Antiphospholipid syndrome and the relationship between laboratory assay positivity and prevalence of nonbacterial thrombotic endocarditis: A retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1408-1414.	3.8	10
43	Prevalence, Indications, and Outcomes of Stacked Vena Cava Filters. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 800-802.	2.0	0
44	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	3.8	60
45	Venous Thromboembolism Prophylaxis: Need for Continuous Assessment Due to Changes in Risk During the Same Hospitalization. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 170-175.	2.4	2
46	DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-analysis. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2021-2026.	2.6	7
47	Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. <i>Current Medical Research and Opinion</i> , 2019, 35, 2043-2051.	1.9	14
48	Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. <i>American Journal of Hematology</i> , 2019, 94, 1185-1192.	4.1	44
49	57-Year-Old Man With Vertigo. <i>Mayo Clinic Proceedings</i> , 2019, 94, e73-e79.	3.0	0
50	Frequency of Bleeding Complications After Percutaneous Core Needle Biopsy and the Association With Aspirin Usage and Length of Aspirin Discontinuation. <i>American Journal of Roentgenology</i> , 2019, 213, 211-215.	2.2	4
51	Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1242-1252.	3.0	26
52	Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2444-2454.	3.0	29
53	Natural history and management outcomes of segmental arterial mediolysis. <i>Journal of Vascular Surgery</i> , 2019, 70, 1877-1886.	1.1	21
54	Neoplastic embolization to systemic and pulmonary arteries. <i>Journal of Vascular Surgery</i> , 2018, 68, 204-212.e7.	1.1	8

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism. <i>European Journal of Haematology</i> , 2018, 101, 136-142.	2.2	25
56	Segmental Arterial Mediolytic: Abdominal Imaging of and Disease Course in 111 Patients. <i>American Journal of Roentgenology</i> , 2018, 210, 899-905.	2.2	44
57	Platelet-predominate gene expression and reticulated platelets in nonvalvular atrial fibrillation: Effect of pulmonary veins isolation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 412-420.	1.7	2
58	Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location. <i>Mayo Clinic Proceedings</i> , 2018, 93, 40-47.	3.0	84
59	Endovascular recanalization for nonmalignant obstruction of the inferior vena cava. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2018, 6, 173-182.	1.6	23
60	In Reply. <i>Obstetrics and Gynecology</i> , 2018, 131, 741-742.	2.4	1
61	Testicular vein thrombosis: Incidence of recurrent venous thromboembolism and survival. <i>European Journal of Haematology</i> , 2018, 100, 83-87.	2.2	9
62	Association of Ankle-Brachial Indices With Limb Revascularization or Amputation in Patients With Peripheral Artery Disease. <i>JAMA Network Open</i> , 2018, 1, e185547.	5.9	21
63	Strengthening the Case for the Role of Thrombophilia in Calciphylaxis. <i>JAMA Dermatology</i> , 2018, 154, 970.	4.1	1
64	The Evolving Treatment of Peripheral Arterial Disease through Guideline-Directed Recommendations. <i>Journal of Clinical Medicine</i> , 2018, 7, 9.	2.4	21
65	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents. <i>Journal of Clinical Medicine</i> , 2018, 7, 29.	2.4	29
66	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	1.4	12
67	Antiphospholipid Syndrome. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2317-2330.	2.8	109
68	Intervention radiology for venous thrombosis: early thrombus removal using invasive methods. <i>British Journal of Haematology</i> , 2017, 177, 173-184.	2.5	11
69	Impact of atrial fibrillation on platelet gene expression. <i>European Journal of Haematology</i> , 2017, 98, 615-621.	2.2	17
70	Effect of atrial fibrillation duration on plasma von Willebrand factor level. <i>European Journal of Haematology</i> , 2017, 99, 569-576.	2.2	4
71	Ovarian Vein Thrombosis. <i>Obstetrics and Gynecology</i> , 2017, 130, 1127-1135.	2.4	40
72	Direct oral anticoagulant medications in calciphylaxis. <i>International Journal of Dermatology</i> , 2017, 56, 1065-1070.	1.0	29

#	ARTICLE	IF	CITATIONS
73	Funambulism and the Art and Science of Periprocedural Anticoagulant Management. Mayo Clinic Proceedings, 2017, 92, 1176-1178.	3.0	1
74	Bleeding Complications following Image-Guided Percutaneous Biopsies in Patients Taking Clopidogrel—A Retrospective Review. Journal of Vascular and Interventional Radiology, 2017, 28, 88-93.	0.5	9
75	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Thrombosis and Haemostasis, 2017, 117, 2135-2145.	3.4	53
76	Real-world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center. Clinical Cardiology, 2017, 40, 1328-1332.	1.8	5
77	Apixaban and dalteparin in active malignancy associated venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 1952-1961.	3.4	62
78	Reasons for the persistent incidence of venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 390-400.	3.4	89
79	An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients. Blood, 2017, 130, 626-626.	1.4	4
80	The Khorana Score for the Prediction of Venous Thromboembolism in Patients with Solid Cancer: An Individual Patient Data Meta-Analysis. Blood, 2017, 130, 627-627.	1.4	3
81	Hypercoagulable Conditions Leading to Limb Ischemia. , 2017, , 267-278.		0
82	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open, 2016, 6, e010569.	1.9	18
83	Periprocedural warfarin reversal with prothrombin complex concentrate. Thrombosis Research, 2016, 139, 160-165.	1.7	14
84	Leukemia cutis imitating venous ulcerations. Vascular Medicine, 2016, 21, 172-173.	1.5	0
85	Association of Soluble CD40 Ligand With Duration of Atrial Fibrillation and With Intensity of Spontaneous Echocardiographic Contrast. JACC: Clinical Electrophysiology, 2016, 2, 623-632.	3.2	8
86	Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. Mayo Clinic Proceedings, 2016, 91, 1384-1394.	3.0	145
87	Calciphylaxis: A Disease of Pannicular Thrombosis. Mayo Clinic Proceedings, 2016, 91, 1395-1402.	3.0	42
88	Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest, 2016, 150, 1302-1312.	0.8	210
89	Periprocedural Anticoagulation Management of Patients with Thrombophilia. American Journal of Medicine, 2016, 129, 986-992.	1.5	4
90	Dabigatran Versus Warfarin in Relation to Renal Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 129-131.	2.8	12

#	ARTICLE	IF	CITATIONS
91	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	334
92	Guidance for the management of venous thrombosis in unusual sites. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 129-143.	2.1	87
93	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 32-67.	2.1	243
94	Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry. <i>American Journal of Medicine</i> , 2016, 129, 615-619.	1.5	60
95	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. <i>Annals of Hematology</i> , 2016, 95, 437-449.	1.8	56
96	Coronary endothelial dysfunction is associated with increased risk of venous thromboembolism. <i>Thrombosis Research</i> , 2016, 139, 17-21.	1.7	20
97	Relationship between body mass index and left atrial appendage thrombus in nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 613-618.	2.1	12
98	Clinical pearls in vascular medicine and anticoagulation. <i>Disease-a-Month</i> , 2015, 61, 356-365.	1.1	0
99	Removal of floating inferior vena cava thrombus with the AngioVac device. <i>Vascular Medicine</i> , 2015, 20, 190-192.	1.5	9
100	The Association Between Thromboembolic Complications and Blood Group in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2015, 90, 216-223.	3.0	9
101	Prevalence and risk factors for post thrombotic syndrome after deep vein thrombosis in children: A cohort study. <i>Thrombosis Research</i> , 2015, 135, 347-351.	1.7	25
102	A patient-centered approach to the development and pilot of a warfarin pharmacogenomics patient education tool for health professionals. <i>Currents in Pharmacy Teaching and Learning</i> , 2015, 7, 249-255.	1.0	6
103	Impact of Atrial Fibrillation and Sinus Rhythm Restoration on Reticulated Platelets. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1650-1658.	3.0	6
104	The impact of gender and left atrial blood stasis on adiponectin levels in non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 181, 207-212.	1.7	9
105	Thrombophilia Testing in Splanchnic Vein Thrombosis. , 2015, , 309-323.		0
106	Abstract 302: Coronary Endothelial Dysfunction Is Associated With Increased Risk of Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	2.4	0
107	Abstract 10879: Efficacy and Safety of Rivaroxaban in Patients With Venous Thromboembolism and Active Malignancy - A Single Center Registry. <i>Circulation</i> , 2015, 132, .	1.6	0
108	Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. <i>Thrombosis and Haemostasis</i> , 2014, 112, 947-950.	3.4	90

#	ARTICLE	IF	CITATIONS
109	Distribution of thromboembolism in valvular versus non-valvular atrial fibrillation. Expert Review of Cardiovascular Therapy, 2014, 12, 1129-1132.	1.5	10
110	Health-related quality of life in children and young adults with post-thrombotic syndrome: Results from a cross-sectional study. Pediatric Blood and Cancer, 2014, 61, 546-551.	1.5	29
111	Science of health care delivery. Vascular Medicine, 2014, 19, 392-393.	1.5	0
112	Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation. Journal of Thrombosis and Thrombolysis, 2014, 37, 532-535.	2.1	3
113	Propensity for young reticulated platelet recruitment into arterial thrombi. Journal of Thrombosis and Thrombolysis, 2014, 37, 148-154.	2.1	58
114	Portal Venous Thrombosis After Distal Pancreatectomy: Clinical Outcomes. Journal of Gastrointestinal Surgery, 2014, 18, 656-661.	1.7	8
115	The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 326.	0.9	2
116	New Anticoagulant and Antiplatelet Agents: A Primer for the Gastroenterologist. Clinical Gastroenterology and Hepatology, 2014, 12, 187-195.	4.4	47
117	Succinct Review of the New VTE Prevention and Management Guidelines. Mayo Clinic Proceedings, 2014, 89, 394-408.	3.0	23
118	Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients. Journal of Thrombosis and Thrombolysis, 2013, 35, 100-106.	2.1	5
119	Thrombophilia differences in splanchnic vein thrombosis and lower extremity deep venous thrombosis in North America. Journal of Gastroenterology, 2013, 48, 1111-1118.	5.1	16
120	Platelet recruitment to venous stent thrombi. Journal of Thrombosis and Thrombolysis, 2013, 36, 442-447.	2.1	1
121	Open surgical removal of a tilted and dislodged inferior vena cava filter through a lumbar branch without cavotomy. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2013, 1, 304-308.	1.6	4
122	Dabigatran: A Primer for Neurosurgeons. World Neurosurgery, 2013, 79, 154-158.	1.3	7
123	Outcomes and total costs of outpatient vs. inpatient peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. International Journal of Cardiology, 2013, 168, 5311-5315.	1.7	8
124	Clinical Manifestations of Fibromuscular Dysplasia Vary by Patient Sex. Journal of the American College of Cardiology, 2013, 62, 2026-2028.	2.8	80
125	Great saphenous vein transposition to the popliteal vein (the May-Husni procedure). Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2013, 1, 82-83.	1.6	4
126	Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures. New England Journal of Medicine, 2013, 368, 2113-2124.	27.0	393

#	ARTICLE	IF	CITATIONS
127	Antithrombotic Therapy and Invasive Procedures. <i>New England Journal of Medicine</i> , 2013, 369, 1077-1080.	27.0	12
128	Surgical Pathology of Hypothetar Hammer Syndrome With New Pathogenetic Insights. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1700-1708.	3.7	34
129	Adrenal haemorrhage due to heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2013, 109, 669-675.	3.4	41
130	Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. <i>Annals of Oncology</i> , 2012, 23, 1998-2005.	1.2	43
131	Periprocedural Bridging Management of Anticoagulation. <i>Circulation</i> , 2012, 126, 486-490.	1.6	73
132	Periprocedural Anticoagulant Management. <i>Hospital Practice (1995)</i> , 2012, 40, 40-49.	1.0	2
133	Septic venous thromboembolism. <i>Vascular Medicine</i> , 2012, 17, 429-430.	1.5	1
134	The United States Registry for Fibromuscular Dysplasia. <i>Circulation</i> , 2012, 125, 3182-3190.	1.6	459
135	Outcomes of Venoplasty with Stent Placement for Chronic Thrombosis of the Iliac and Femoral Veins: Single-Center Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1009-1015.	0.5	72
136	Development and initial validation of a questionnaire to diagnose the presence and severity of postâ€thrombotic syndrome in childre. <i>Pediatric Blood and Cancer</i> , 2012, 58, 643-644.	1.5	9
137	Predictors of major bleeding in periâ€procedural anticoagulation management. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 261-267.	3.8	101
138	Natural language processor as a tool to assess heparin induced thrombocytopenia awareness. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 95-100.	2.1	2
139	Thrombophilia Effect On Periprocedural Thromboembolism and Bleeding in Chronically Anticoagulated Patients. <i>Blood</i> , 2012, 120, 3404-3404.	1.4	0
140	Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. <i>Circulation</i> , 2011, 124, 695-703.	1.6	69
141	The Association of Active Cancer With Venous Thromboembolism Location: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2011, 86, 25-30.	3.0	45
142	Platelet factor XIII gene expression and embolic propensity in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2011, 106, 75-82.	3.4	13
143	Fibrin D-Dimer Concentration, Deep Vein Thrombosis Symptom Duration, and Venous Thrombus Volume. <i>Angiology</i> , 2011, 62, 253-256.	1.8	25
144	Left Atrial Blood Stasis and Von Willebrand Factorâ€ADAMTS13 Homeostasis in Atrial Fibrillation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2760-2766.	2.4	42

#	ARTICLE	IF	CITATIONS
145	Budd-Chiari syndrome, mediastinal mass and recalcitrant leg ulcers, an unlikely trio. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 226-228.	2.1	1
146	Comparison of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer Levels in Various Age Decades in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease (from the BARI 2D Trial). <i>American Journal of Cardiology</i> , 2010, 105, 17-24.	1.6	36
147	Periprocedural Anticoagulation Management of Patients With Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 442-448.	2.4	62
148	Health Status After Treatment for Coronary Artery Disease and Type 2 Diabetes Mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. <i>Circulation</i> , 2010, 122, 1690-1699.	1.6	42
149	Survival and Recurrence in Patients With Splanchnic Vein Thromboses. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 200-205.	4.4	168
150	Acquired and Congenital Risk Factors associated with Cerebral Venous Sinus Thrombosis. <i>Thrombosis Research</i> , 2010, 126, 81-87.	1.7	33
151	Predicting left atrial thrombi in atrial fibrillation. <i>American Heart Journal</i> , 2010, 159, 665-671.	2.7	72
152	Inhibition of Platelet-Rich Arterial Thrombus In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1271-1276.	2.4	29
153	Brain Lesions in Cerebral Venous Sinus Thrombosis. <i>Stroke</i> , 2009, 40, 1509-1511.	2.0	42
154	Popliteal venous aneurysm. <i>Vascular Medicine</i> , 2009, 14, 283-284.	1.5	2
155	Correlation of Point-of-Care International Normalized Ratio to Laboratory International Normalized Ratio in Hemodialysis Patients Taking Warfarin. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 99-104.	4.5	18
156	Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. <i>Thrombosis Research</i> , 2009, 124, 300-305.	1.7	55
157	Arteriovenous Malformation. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1743.	2.8	0
158	Treatment of venous thrombosis at unusual sites. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 136-145.	0.9	14
159	Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis. <i>American Journal of Kidney Diseases</i> , 2008, 51, 224-232.	1.9	65
160	Platelet activation and its patient-specific consequences. <i>Thrombosis Research</i> , 2008, 122, 435-441.	1.7	6
161	Individual propensity for thrombosis: Comparison of venous and arterial circulations. <i>Thrombosis Research</i> , 2008, 122, 390-396.	1.7	6
162	Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2008, 83, 639-645.	3.0	49

#	ARTICLE	IF	CITATIONS
163	Accuracy of Capillary Whole Blood International Normalized Ratio on the CoaguChek S, CoaguChek XS, and i-STAT 1 Point-of-Care Analyzers. <i>American Journal of Clinical Pathology</i> , 2008, 130, 88-92.	0.7	36
164	Iliac Venous Stenting. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 413-418.	2.4	26
165	Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2008, 83, 639-645.	3.0	74
166	Clinical and echocardiographic measures governing thromboembolism destination in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2008, 99, 951-955.	3.4	30
167	Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 2008, 99, 759-766.	3.4	9
168	Acute venous disease: Venous thrombosis and venous trauma. <i>Journal of Vascular Surgery</i> , 2007, 46, S25-S53.	1.1	113
169	Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2007, 46, 62-70.	1.1	32
170	Ovarian vein thrombosis: Incidence of recurrent venous thromboembolism and survival. <i>Thrombosis and Haemostasis</i> , 2006, 96, 126-131.	3.4	129
171	Immunohistochemistry of thrombi following iliac venous stenting: A novel model of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2006, 96, 618-622.	3.4	15
172	Images in vascular medicine. <i>Vascular Medicine</i> , 2006, 11, 173-174.	1.5	3
173	Ovarian vein thrombosis: incidence of recurrent venous thromboembolism and survival. <i>Thrombosis and Haemostasis</i> , 2006, 96, 126-31.	3.4	27
174	Immunohistochemistry of thrombi following iliac venous stenting: a novel model of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2006, 96, 618-22.	3.4	4
175	Early Subclinical Coronary Artery Calcification in Young Adults Who Were Pediatric Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1689-1693.	4.7	43
176	Cardiomyopathy Associated With Celiac Disease. <i>Mayo Clinic Proceedings</i> , 2005, 80, 674-676.	3.0	24
177	Importance of Device Evaluation for Point-of-Care Prothrombin Time International Normalized Ratio Testing Programs. <i>Mayo Clinic Proceedings</i> , 2005, 80, 181-186.	3.0	33
178	Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis. <i>Thrombosis Research</i> , 2005, 116, 525-532.	1.7	7
179	Images in vascular medicine. <i>Vascular Medicine</i> , 2004, 9, 315-317.	1.5	2
180	Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1637-1644.	3.8	64

#	ARTICLE	IF	CITATIONS
181	The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1834-1841.	3.8	2
182	Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). <i>Journal of the American College of Cardiology</i> , 2004, 44, 2410-2411.	2.8	80
183	The impact of peripheral arterial disease on circulating platelets. <i>Thrombosis Research</i> , 2004, 113, 137-145.	1.7	23
184	Registration, segmentation, and visualization of confocal microscopy images of arterial thrombus. , 2004, , .		0
185	Patients with a History of Type II Heparin-Induced Thrombocytopenia with Thrombosis Requiring Cardiac Surgery with Cardiopulmonary Bypass: A Prospective Observational Case Series. <i>Anesthesia and Analgesia</i> , 2003, 96, 344-350.	2.2	26
186	Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. <i>Thrombosis and Haemostasis</i> , 2003, 90, 483-490.	3.4	89
187	Factors Contributing to Individual Propensity for Arterial Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1495-1499.	2.4	38
188	Antiphospholipid antibodies in thromboangiitis obliterans. <i>Vascular Medicine</i> , 2002, 7, 259-264.	1.5	53
189	Influence of Anatomical Location on Arterial Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 342-347.	2.4	12
190	Efficacy and Safety of Intravenous Phytonadione (Vitamin K1) in Patients on Long-term Oral Anticoagulant Therapy. <i>Mayo Clinic Proceedings</i> , 2001, 76, 260-266.	3.0	62
191	Surgical Pathology of Nonbacterial Thrombotic Endocarditis in 30 Patients, 1985â€“2000. <i>Mayo Clinic Proceedings</i> , 2001, 76, 1204-1212.	3.0	119
192	Aortic Thrombosis as a Complication of Paroxysmal Nocturnal Hemoglobinuria. <i>Circulation</i> , 2001, 104, E1-2.	1.6	28
193	Fibrinogen, Fibrin and Crosslinking in Aging Arterial Thrombi. <i>Thrombosis and Haemostasis</i> , 2000, 84, 83-87.	3.4	24
194	Antiphospholipid Syndrome and Perioperative Hemostatic Management of Cardiac Valvular Surgery. <i>Mayo Clinic Proceedings</i> , 2000, 75, 971-976.	3.0	40
195	Individual Propensity for Arterial Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 883-886.	2.4	10
196	Elevated liver enzymes preceding vessel involvement in Takayasu's arteritis. <i>Journal of Hepatology</i> , 1999, 30, 349-350.	3.7	9
197	Tissue Prothrombin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2430-2436.	2.4	27
198	Reversibility of Platelet Thrombosis In Vivo. <i>Thrombosis and Haemostasis</i> , 1996, 76, 1108-1113.	3.4	29

#	ARTICLE	IF	CITATIONS
199	Antithrombotic Action of Endogenous Porcine Protein C Activated with a Latent Porcine Thrombin Preparation. <i>Thrombosis and Haemostasis</i> , 1995, 74, 879-885.	3.4	13
200	Herpes esophagitis: clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. <i>Gastrointestinal Endoscopy</i> , 1991, 37, 600-603.	1.0	128